TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BioInvent International AB ( (SE:BINV) ) just unveiled an update.
BioInvent International AB announced the presentation of updated Phase 2a data for its BI-1808 monotherapy at the 2025 ASH Annual Meeting. The data highlights the treatment’s promising efficacy and safety profile in cutaneous T-cell lymphoma (CTCL), with no severe adverse events reported and a high disease control rate. BI-1808 has received Fast Track and Orphan Drug Designations from the FDA, underscoring its potential impact on patients with unmet medical needs.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK34.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
More about BioInvent International AB
BioInvent International AB is a clinical-stage biotech company specializing in the discovery and development of novel, first-in-class immuno-modulatory antibodies for cancer therapy. The company is engaged in Phase 1/2 trials targeting hematological cancer and solid tumors, utilizing its proprietary F.I.R.S.T™ technology platform to identify promising candidates for its clinical pipeline and partnership opportunities.
YTD Price Performance: -17.27%
Average Trading Volume: 98,276
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.1B
For detailed information about BINV stock, go to TipRanks’ Stock Analysis page.